Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Related LGND
UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On Biopharma
Hedge Fund Guru Emmanuel Lemelson Just Revealed How He's Trading Apple (And 3 Other Stocks)
Related GSK
Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines
#PreMarket Primer: Thursday, December 4: Beige Book Paints Positive Picture Of U.S. Economy
Action in Ebola-Related Stocks (Fox Business)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Related Articles (LGND + GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters